Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 18/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.75 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.75 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.75 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.75 |
| ▸ | MLNR | O43193 | 1/20 | 0.75 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.75 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
| ▸ | PGR | P06401 | 1/20 | 0.75 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.75 |
| ▸ | HTR1A | P08908 | 1/20 | 0.75 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3716311 | 1.00 | CYP3A4 (0.75) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 | |
| SCHEMBL3304792 | 1.00 | CYP3A4 (0.75) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 | |
| SCHEMBL8269408 | 0.97 | CYP3A4 (0.77) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 | |
| SCHEMBL2913540 | 0.97 | CYP3A4 (0.77) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 | |
| SCHEMBL13748639 | 0.89 | CYP3A4 (0.69) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 | |
| SCHEMBL13749205 | 0.89 | CYP3A4 (0.69) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 | |
| SCHEMBL3039096 | 0.89 | CYP3A4 (0.71) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 | |
| SCHEMBL2916535 | 0.88 | CYP3A4 (0.67) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 | |
| SCHEMBL7091785 | 0.87 | CYP3A4 (0.81) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 | |
| SCHEMBL2736324 | 0.87 | CYP3A4 (0.77) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1240903-A2 | Combination of calcium (3S) tetrahydro-3-furanyl(1S,2R)-3- [[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy) propylcarbamate with ritonavir | GLAXO GROUP LIMITED (GB) | 2002-09-18 | — | — | EP | claimed |
| US-20240148729-A1 | LOPINAVIR AND RITONAVIR FOR THE TREATMENT OF CERVIX DISORDERS | DOUGLAS PHARMACEUTICALS LIMITED (NZ) | 2024-05-09 | — | — | US | disclosed |
| WO-2024050019-A2 | PROCESSES FOR PREPARING SOLID STATE FORMS | VARDA SPACE INDUSTRIES, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| US-11045423-B2 | Anti-retroviral compositions | HETERO LABS LIMITED (IN) | 2021-06-29 | — | — | US | disclosed |
| US-20190175508-A1 | ANTI-RETROVIRAL COMPOSITIONS | HETERO LABS LIMITED (IN) | 2019-06-13 | — | — | US | disclosed |
| US-20190175509-A1 | High Drug Loaded Tablet Composition for Treating HIV | HETERO LABS LIMITED (IN) | 2019-06-13 | — | — | US | disclosed |
| WO-2019046287-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING OR PREVENTING HEPATITIS B | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-03-07 | — | — | WO | disclosed |
| WO-2015125082-A1 | IMPROVED PROCESS FOR THE PREPARATION OF RITONAVIR | MYLAN LABORATORIES LIMITED (IN) | 2015-08-27 | — | — | WO | disclosed |
| EP-2819668-A1 | RITONAVIR COMPOSITIONS | Hetero Research Foundation (IN) | 2015-01-07 | — | — | EP | disclosed |
| WO-2014184553-A1 | PHARMACEUTICAL ANTIRETROVIRAL COMPOSITIONS | CIPLA LIMITED (IN) | 2014-11-20 | — | — | WO | disclosed |
| WO-2001082919-A2 | METHODS OF AND COMPOUNDS FOR INHIBITING CALPAINS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-11-08 | — | — | WO | disclosed |
| EP-1098898-A1 | CALCIUM (3S) TETRAHYDRO-3-FURANYL(1S,2R)-3- (4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO] -1-BENZYL-2- (PHOSPHONOOXY) PROPYLCARBAMATE | GLAXO GROUP LIMITED (GB) | 2001-05-16 | — | — | EP | disclosed |
| WO-2001000635-A2 | DERIVATIVES OF (3S) TETRAHYDRO-3-FURANYL (1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](ISOBUTYL)AMINO]-1-BENZYL-2-(PHOSPHONOOXY)PROPYLCARBAMATE | GLAXO GROUP LIMITED (GB) | 2001-01-04 | — | — | WO | disclosed |
| EP-1019056-A1 | ANTIVIRAL COMBINATIONS CONTAINING THE CARBOCYCLIC NUCLEOSIDE 1592U89 | GLAXO GROUP LIMITED (GB) | 2000-07-19 | — | — | EP | disclosed |
| EP-0979082-A1 | ANTIVIRAL COMBINATIONS CONTAINING THE CARBOCYCLIC NUCLEOSIDE 1592U89 | GLAXO GROUP LIMITED (GB) | 2000-02-16 | — | — | EP | disclosed |
| WO-2000004033-A1 | CALCIUM (3S) TETRAHYDRO-3-FURANYL(1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO] -1-BENZYL-2- (PHOSPHONOOXY) PROPYLCARBAMATE | GLAXO GROUP LIMITED (GB) | 2000-01-27 | — | — | WO | disclosed |
| EP-0906107-A1 | COMPOSITIONS COMPRISING AN HIV PROTEASE INHIBITOR SUCH AS VX 478 AND A WATER SOLUBLE VITAMIN E COMPOUND SUCH AS VITAMIN E-TPGS | GLAXO GROUP LIMITED (GB) | 1999-04-07 | — | — | EP | disclosed |
| WO-1998052570-A1 | ANTIVIRAL COMBINATIONS CONTAINING THE CARBOCYCLIC NUCLEOSIDE 1592U89 | GLAXO GROUP LIMITED (GB) | 1998-11-26 | — | — | WO | disclosed |
| WO-1998052571-A1 | ANTIVIRAL COMBINATIONS CONTAINING THE CARBOCYCLIC NUCLEOSIDE 1592U89 | GLAXO GROUP LIMITED (GB) | 1998-11-26 | — | — | WO | disclosed |
| WO-1997035587-A1 | COMPOSITIONS COMPRISING AN HIV PROTEASE INHIBITOR SUCH AS VX 478 AND A WATER SOLUBLE VITAMIN E COMPOUND SUCH AS VITAMIN E-TPGS | GLAXO GROUP LIMITED (GB) | 1997-10-02 | — | — | WO | disclosed |